Vice Admiral Mary Jackson Named to Jacobs Board of Directors
Jacobs (NYSE:J) announced today the election of Mary Jackson to its Board of Directors, effective upon the closing of the previously announced separation of Jacobs' Critical Mission Solutions and portions of its Divergent Solutions business, or, if earlier, January 15, 2025. A 32-year veteran of the United States Navy with extensive experience as an advisor across numerous boards while in the Navy and since, retired Vice Admiral Jackson brings a proven track record of dynamic leadership discipline, strategic business continuity and operational efficiency.
View more
Jacobs Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Critical Mission Solutions and Cyber & Intelligence Businesses and Merger with Amentum
Jacobs (NYSE: J) has announced that a Form 10 has been publicly filed with the U.S. Securities and Exchange Commission ("SEC") for the previously announced planned spin-off of its Critical Mission Solutions and portions of its Divergent Solutions business, including the Cyber & Intelligence business. Filed under Amazon Holdco Inc., the Form 10 describes the spin-off and merger with Amentum Parent Holdings LLC ("Amentum"), to create a leading, publicly traded global engineering and technology solutions provider. The transaction is expected to close in the second half of the fourth quarter of fiscal year 2024. Upon closing, the combined company will be known as Amentum Holdings, Inc.
View more
Regulatory Considerations for Delivering ATMP Multi-Model Facilities
With the emergence of new medical treatments and therapies reaching the market, and thousands of new therapies also in preclinical and clinical stages, pharmaceutical manufacturing companies are looking to implement multi-model and flexible facilities. Jacobs’ Julie Vickers, Todd Rumsey, Peter Cramer and Francesca McBride discuss how to determine compatibility and congruence between primary and alternative modalities to deliver products with different manufacturing requirements and deliver transformative medicines to patients, faster.
View more